Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
N. Schlesinger, D.G. Baker, H.R. Schumacher.
How well have diagnostic tests and therapies for gout been evaluated?.
Curr Op Rheumatol, 11 (1999), pp. 441-445
[2.]
A.G. Fam.
Should patients with interval gout be treated with urate lowering drugs?.
J Rheumatol, 22 (1995), pp. 1621-1623
[3.]
M. Bosi-Ferraz.
An evidence based appraisal of the management of nontophaceous interval gout.
J Rheumatol, 22 (1995), pp. 1618-1620
[4.]
F. Pérez Ruiz, M. Calabozo.
Gota secundaria. Seminarios de la Fundación Española de Reumatología, 1 (2000), pp. 103-111
[5.]
F. Pérez Ruiz, A. Ruibal Escribano, A. Herrero Beites, M. Calabozo Raluy.
Resultado del tratamiento hipouricemiante de la gota en ancianos.
Rev Esp Reumatol, 28 (2001), pp. 321-324
[6.]
F. Pérez-Ruiz, M. Calabozo, A. Herrero-Beites, G. García-Erauskin, J.I. Pijoan.
Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts.
Nephron, 86 (2000), pp. 287-291
[7.]
J. Darmawan, J.J. Rasker, H. Nuralim.
The effect of control and self-medication of chronic gout in a developing country. Outcome after 10 years.
J Rheumatol, 30 (2003), pp. 2437-2443
[8.]
Agencia Española del Medicamento. Comunicación sobre riesgos de medicamentos para profesionales sanitarios. Restricción del uso de benzbromarona y suspensión de comercialización de benziodarona y de las asociaciones benzbromarona-alopurinol. Nota informativa. 10 febrero, 2004/02.
[9.]
G.M. McCarthy, C.R. Barthelemy, J.A. Veum, R.L. Wortmann.
Influence of antihyperuricemic therapy on the clinical and radiographic progression of gout.
Arthritis Rheum, 34 (1991), pp. 1489-1495
[10.]
F. Pérez-Ruiz, M. Calabozo, M.J. Fernández-López, A. Herrero-Beites, E. Ruiz-Lucea, G. García-Erauskin, et al.
Treatment of chronic gout in patients with renal function impairment. An open, randomized, actively controlled study.
J Clin Rheumatol, 5 (1999), pp. 49-55
[11.]
L. Stamp, P. Gow, K. Sharples, B. Raill.
The optimal use of allopurinol: an audit of allopurinol use in South Auckland.
Aust NZ J Med, 30 (2000), pp. 567-572
[12.]
F. Pérez-Ruiz, P. Gómez-Ullate, J.J. Amenabar, S. Zarraga, M. Calabozo, A.M. Herrero-Beites, et al.
Long-term efficacy of hyperuricemia treatment in renal transplant patients.
Nephrol Dial Transplant, 18 (2003), pp. 603-606
[13.]
P.A. Simkin.
Allopurinol and beyond.
J Clin Rheumatol, 5 (1999), pp. 52-54
[14.]
J.S. Bomalaski, F.W. Holtsberg, C.M. Ensor, M.A. Clark.
Uricase formulated with polyethylene glicol Uuricase (PEG 20): biochemical rationale and preclinical studies.
J Rheumatol, 29 (2002), pp. 1942-1949
[15.]
M.A. Becker, H.R. Schumacher, R.L. Wortmann, P.A. McDonald, W.A. Palo, D. Eustace, et al.
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. A twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
Arthritis Rheum, 52 (2005), pp. 916-923
[16.]
F. Pérez-Ruiz, I. Hernando, I. Villar, J.M. Nolla.
Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels. Another insight to allopurinol-related toxicity.
J Clin Rheumatol, 11 (2005), pp. 129-133
[17.]
T.R. Mikuls, C.H. MacLean, J. Oliveri, F. Patino, J.J. Allison, J.T. Farrar, et al.
Quality of care indicators for gout management.
Arthritis Rheum, 50 (2004), pp. 937-943
[18.]
A.B. Gutman.
Uricosuric drugs, with special reference to probenecid and sulfinpyrazone.
Adv Pharmacol, 4 (1966), pp. 91-142
[19.]
L.B. Sorensen, D.J. Levinson.
Evaluation of benzbromarone. A new uricosuric drug.
Arthritis Rheum, 19 (1976), pp. 183-189
[20.]
F. Pérez Ruiz, M. Calabozo Raluy, A. Ruibal Escribano, A. Alonso Ruiz, L. Garrido Courel, I. Hernando Ruibio, et al.
La monitorización de la concentración de ácido úrico no disociado en orina permite minimizar el riesgo de litiasis renal durante el tratamiento con uricosúricos.
Rev Esp Reumatol, 31 (2004), pp. 228-229
[21.]
F. Pérez Ruiz, M. Calabozo, J.I. Pijoan, A. Herrero-Beites, A. Ruibal.
Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
Arthritis Rheum, 47 (2002), pp. 356-360
[22.]
F. Pérez Ruiz, M. Calabozo Raluy, J.I. Pijoan Zubizarreta, A. Alonso Ruiz, L. Garrido Courel, A. Ruibal Escribano, et al.
Recidiva de la gota tras la suspensión del tratamiento hipouricemiante: nuevas perspectivas para el tratamiento intermitente.
Rev Esp Reumatol, 31 (2004), pp. 228
[23.]
M.F. Van Lieshout-Zuidema, F.C. Breedveld.
Withdrawal of longterm hypouricemic therapy in tophaceous gout.
J Rheumatol, 20 (1993), pp. 1383-1385
[24.]
K.L. Wallace, A.A. Riedel, N. Joseph-Ridge, M. Nelson, P.A. MacDonald, M. Becker.
Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims.
Arthritis Rheum, 48 (2003), pp. S1587
[25.]
F. Pérez Ruiz, M. Calabozo Raluy, A. Alonso Ruiz, A. Ruibal Escribano, L. Garrido Courel, I. Hernando Ruibio, et al.
Factores determinantes del abandono del tratamiento hipouricemiante en pacientes con gota crónica.
Rev Esp Reumatol, 31 (2004), pp. 272
[26.]
H.K. Choi, K. Atkinson, E.W. Karlson, W. Willatt, G. Curhan.
Purine-rich food, dairy and vegetal protein intake, and the risk of gout.
N Engl J Med, 350 (2004), pp. 1093-1103
Copyright © 2005. Elsevier España S.L. Barcelona
